Keya Medical’s President of R&D, Dr. Kunlin Cao, has been recognized on the 2021 Forbes China Up-and-Coming Businesswomen list. The list highlights 20 accomplished women who have each played a significant role in shaping China’s business landscape.
Keya Medical has raised $46 million in Series D funding. This funding round was led by new and existing investors, including CICC Capital, Shanghai Artificial Intelligence Investment Fund, Qianhai Gaozu Asset Management Fund, and IN CAPITAL.
Keya Medical is Named One of the Top 50 Global Healthcare Technology Companies at World Innovators Meet 2020
Keya Medical, a leading medical AI technology company, was recognized as one of the top 50 Global Healthcare Technology Companies at the 2020 World Innovators Meet (WIM) conference held By Equal Ocean in Beijing from December 9-11.
Keya Medical announced that it has completed a $30 Million Series C Funding Round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
On Oct. 17 and 18, the Chengdu Science and Technology Bureau hosted the 2020 DEMO China Innovation Finals, bringing together leading companies across the country.
On Sept. 18, Keya Medical was recognized as the winner of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.